Douglas Farmer, MD
Transplant Surgery · Los Angeles, CANPI 1679508923
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,173 of the $2,553 with a category attached, or 85.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 90.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,173 and has fallen 91.8% since, to $179 in 2024. That places this record below the midpoint for transplant surgery clinicians in CA, where the typical reported total is $2,317.
Across 14 payments — averaging $182.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Edwards Lifesciences$173
- Gilead$44
- Stryker$16
- Abbott$13
Across 205 payments — averaging $2048.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$365K
- Shire North American Group Inc$55K
What the payments were for
- Consulting fees$2,17385%
- Food & beverage$38015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $2,307 |
| Edwards Lifesciences | 6 | $173 |
| Gilead | 1 | $44 |
| Stryker | 1 | $16 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GATTEX$2,173
- EDWARDS INTUITY Elite valve system$121
How this compares
$2,553 in reported general payments places this provider in the 50th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Los Angeles
- Yuri GenykLos Angeles$35K
- Navpreet KaurLos Angeles$19K
- Gerald LipshutzLos Angeles$16K
- Mohd SheikhLos Angeles$9K
- Fady KaldasLos Angeles$7K
- Jim KimLos Angeles$6K
- Aaron AhearnLos Angeles$5K
- Juliet EmamaulleeLos Angeles$4K
- Linda SherLos Angeles$3K
- Kambiz EtesamiLos Angeles$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.